溃克灵治疗溃疡性结肠炎药效及免疫机理研究
|
摘要
溃疡性结肠炎(UC)是一种直肠和结肠粘膜的炎症性肠病(IBD),病因尚不明确,是易感基因、环境和免疫系统等相互作用导致的复杂疾病,免疫系统的参与在UC的病机发展中起重要作用。随着免疫学、分子生物学等学科的迅速发展,以及近年来对细胞因子、粘附分子的研究,UC的发病机制正逐步得以揭示。对于UC的治疗,中药与西药发挥着相似的作用。但是,中药治疗UC极少发生西药治疗所引起的易复发、具有毒副作用等方面的问题。中医药治疗UC在临床发挥着不可轻视的作用。中医药在治疗UC方面具有广阔的研究空间,中医药治疗UC的实验研究尤其是作用机理的研究是目前中医药治疗UC的重点。
溃克灵(KKL)是在南京市鼓楼医院消化科多年临床经验基础上总结出的用于治疗UC的有效中药复方。我们认为脾虚是UC发病之本,湿热邪毒为致病之标,气滞血瘀贯穿始终,脾肾阳虚是本病主要转归和病情迁延不愈的重要因素。KKL具有健脾益气、清热祛湿、活血化瘀的功效,临床应用显示较好的疗效,无明显毒副作用。KKL先期实验研究已经证实,中药KKL对TNBS法灌肠复制模型大鼠结肠炎的发生具有一定预防保护作用,能明显减少大鼠结肠溃疡个数和面积,改善结肠粘膜炎症和水肿等病理变化,可能与下调CD4~+/CD8~+比值、抑制促炎因子IL-1β分泌和促进抗炎因子IL-10分泌等免疫调节机制有关。为了进一步研究溃克灵治疗溃疡性结肠炎药效及免疫机理,我们选择了溃克灵治疗溃疡性结肠炎药效及免疫机理研究,这一研究将使中医药治疗UC的机理研究深入到基因调控水平,并为开发高质量的抗UC中药新药打下坚实的基础,有重要的理论意义和广阔的应用前景。
本论文分上、下两篇对KKL治疗UC进行了理论和实验研究。
上篇理论研究:
1.中医学对溃疡性结肠炎的研究现状
对中医学关于UC的病名的认识、病因病机的认识及治疗现状进行了全面综述。并根据UC的主要临床表现,经严密剖析与推理,提出我们的观点:脾虚湿盛是UC发病的基本病机,贯穿UC的始终。
2.白介素在溃疡性结肠炎发病机制中的研究进展
白介素(IL)是细胞因子中最主要的具有多种生物活性的一组淋巴因子,并在免疫细胞的发育、分化、免疫应答及某些细胞的激活过程中有重要调节作用。目前研究表明IL主要通过影响机体整体和/或局部免疫系统的功能介导UC的产生,并与UC的迁延难愈和反复发作有关。本文分别对促炎细胞因子和抗炎细胞因子在UC发病机制中的研究进展及中药调控作用做以综述。
3.ICAM-1在IBD炎症过程中的表达及作用
粘附分子(AM)是一类介导细胞与细胞、细胞与细胞外基质间粘附作用的,具有多种生物功能的膜表面糖蛋白。其中内皮细胞黏附分子-1(ICAM-1)属于免疫球蛋白超家族,在IBD发病中的作用近年来受到关注。本文阐述了ICAM-1的生物学特性、在炎症中的作用、在IBD中的表达及作用、抗细胞粘附分子抗体在IBD治疗中的研究、中药通过干预ICAM-1表达治疗UC实验大鼠的研究等几个方面内容。
下篇实验研究:
1.研究内容
1.1溃克灵治疗溃疡性结肠炎主要药效学研究
①分别从溃克灵对TNBS法UC模型大鼠一般表现的影响,体重增长率的影响,结肠病理组织学的影响三方面观察溃克灵对实验性溃疡性结肠炎大鼠的影响;
②分别从溃克灵对巴豆油混合致炎剂所致小鼠耳廓肿胀的影响,对腹腔注射醋酸所致小鼠腹腔毛细血管通透性增高的影响,对大鼠塑料环肉芽肿的影响三方面观察溃克灵的抗炎作用;
③分别采用热板法测定溃克灵对小鼠痛阈值和对小鼠痛阈提高百分率的影响,醋酸扭体法测定溃克灵对小鼠扭体次数的影响观察溃克灵的镇痛作用。
1.2溃克灵治疗溃疡性结肠炎免疫机理研究
①分别从2.5二甲苯致耳肿胀,角叉菜胶致足肿胀,大鼠腹腔白细胞游走三方面观察溃克灵对迟发性超敏反应的影响;
②分别从溃克灵对TNBS法UC模型大鼠血清IL-8含量、血液流变学、结肠黏膜NO含量、NOS活性、结肠组织ICAM-1基因表达、外周血和肠系膜淋巴结CD_4~+CD_(25)~+调节性T细胞数量等几方面观察溃克灵对实验性UC大鼠的免疫调节作用。
2.主要研究方法
将健康Wisater大白鼠随机分成六组,即正常对照组、模型组、溃克灵大剂量组、溃克灵中剂量组、溃克灵小剂量组、柳氮磺胺吡啶组。采用TNBS/乙醇溶液(100mg/kgTNBS+50%的乙醇0.25ml)灌肠法造模。按人与动物等效剂量,分别对各组大鼠进行中、西药及生理盐水灌胃,每日一次,连续三周。第3周末处死大鼠,采集血液与结肠组织标本,检测相关指标;急性炎症模型、慢性肉芽肿病理模型建立,检测相关指标;热板法和扭体法观察溃克灵镇痛作用。
2.结果
一般状态:正常组大鼠明显优于模型组大鼠,治疗组用药1周左右能明显改善模型组大鼠的状态。
光镜观察:正常组结肠各层结构清晰,无炎性改变。模型组结肠粘膜炎症显著,重者有严重溃疡形成。各治疗组(包括KKL各组、SASP组)炎症程度均有改善(P＜0.01,P＜0.05)。
抗炎作用:KKL各剂量组均能抑制巴豆油所致小鼠耳廓肿胀反应,能抑制HAc所引起小鼠腹腔毛细血管通透性的增高,降低大鼠塑料环肉芽肿湿重和干重,有抗肉芽组织形成作用(P＜0.01,P＜0.05)。
镇痛作用:KKL各剂量组均能提高热板法大鼠痛阈值,尤其在给药后1h效果最明显,KKL高、中剂量能明显减少醋酸所致小鼠扭体次数,(P＜0.01,P＜0.05)。
对迟发型变态反应的影响:KKL各剂量组均对二甲苯致小鼠耳廓肿胀有极显著的抑制作用,对角叉菜胶致足肿胀有极显著的抑制作用,对腹腔注射羧甲基纤维素钠引起的白细胞在腹腔游出、聚集有显著抑制作用(P＜0.01,P＜0.05)。
血清IL-8含量:与正常组相比,模型组大鼠血清IL-8水平显著增高(P＜0.01);与模型组相比,各治疗组血清IL-8水平显著降低(P＜0.01)。
结肠黏膜NO含量、NOS活性:与正常组相比,模型组大鼠结肠黏膜NO含量、NOS活性显著增高(P＜0.01);与模型组相比,各治疗组(包括KKL各组、SASP组)结肠黏膜NO含量、NOS活性显著降低(P均＜0.01)。
结肠组织ICAM-1基因表达:与正常组相比,模型组大鼠结肠组织中ICAM-1基因表达显著增高(P＜0.01),而溃克灵大剂量组、SASP组较模型组明显降低(P＜0.01)。
血液流变学变化:与正常组相比,模型组大鼠全血粘度、血浆粘度和红细胞压积均明显增高(P＜0.01)。与模型组相比,溃克灵三个剂量组均能显著降低造模大鼠全血粘度、血浆粘度和红细胞压积(P＜0.01,P＜0.05)。
CD_4~+ CD_(25)~+调节性T细胞:与正常组相比,模型组外周血和肠系膜淋巴结CD_4~+ CD_(25)~+调节性T细胞数量明显下降(P＜0.01),而溃克灵高、中剂量组、SASP组较模型组明显增高(P＜0.01,P＜0.05)。
3.结论
采用TNBS/乙醇溶液(100mg/kgTNBS+50%的乙醇0.25ml)灌肠法复制UC大鼠模型成功,完全符合实验要求。以健脾祛湿为主要功用的KKL对实验性UC大鼠治疗效果肯定,不论在一般状态、病理状态、抗炎、镇痛等方面均显示出中医药治疗溃疡性结肠炎具有较大优势,进而说明脾虚湿盛是UC发病的基本病机,其疗效的产生与该方能抑制迟发型变态反应、降低结肠黏膜NO含量、NOS活性、下调炎性细胞因子IL-8、下调细胞间粘附分子ICAM-1的表达、改善造模大鼠血液流变学及提高CD_4~+ CD_(25)~+调节性T细胞数量有关,明确了KKL治疗UC的部分作用机制,开拓了中医药治疗UC的新思路。
Ulcerative colitis(UC) is an inflammatory bowel disease of the rectal and colonic mucosa.The aetiology of UC remains unknown.UC seems to result from a complex series of interactions between susceptibility genes,the environment and the immune system.An involvement of the immune system plays an important role in the pathogenesis of UC.With the fast development of immunology,molecular biology and investigation of cytokines,adherence factor,the mechanism of UC has been revealed step by step.Therapeutic effect of traditional Chinese medicine(TCM) on UC was similar to than of Western medicine.But the defect of Western medicine such as easy recurrence,toxicity and side effects were seldom found in using TCM. The prospect of utilization and development of TCM is cheerful.The key point of investigation on treating UC with TCM was empirical studied on mechanism of action.
Kuikeling decoction(KKL) was summarized for the treatment of UC effective Chinese herbal compound in Gastro enterology of Nanjing Drum Tower Hospital on the basis years of clinical experience.We consider spleen deficiency are the root of UC,and the fire,humid,food stasis are the tip of UC.The therapeutic principle of the decoction was clearing away heat,removing humid,invigorating the spleen and activating blood.It showed affirmative therapeutic effect on patients without obvious toxicity and side effects.In the past investigation,effect of KKL on UC model rats induced by TNBS was observed.It was observed that the number and area of ulcer model rats were significantly reduced with the administration of KKL.Pathological changes such as inflammatory cell infiltration and edema were improved.It showed affirmative curative effect of KKL on treating UC model rats induced by TNBS.In order to further study the treatment of ulcerative colitis KKL efficacy and immune mechanism,we have chosen the ulcer treatment of ulcerative colitis KKL efficacy and mechanism of immunity.This research will enable the Chinese medicine treatment of UC into the mechanism of gene regulation level,and for the development of high-quality anti-UC Chinese medicine and lay a solid foundation, there are important theoretical significance and wide application prospects.
In this paper,upper and lower two pairs of ulcer treatment kling UC theoretical and experimental studies.
The study in theory
1.The status of UC in Traditional Chinese medicine(TCM)
It is rounded up thoroughly about the knowledge of name of disease of UC, cause of disease and pathogenesis and the status of treatment in TCM.We put up with our viewpoint that is the weak spleen and stomach,hygrothermal intrinsic is the fundamental pathogenesis of UC and has during UC by the main clinical manifestation.
2.Interleukin in the pathogenesis of ulcerative colitis Research Progress
Interleukin(IL) is the most important cytokine with multiple biological activity of a group of lymphokines and immune cells in the development,differentiation, immune response and certain cells in the activation process as an important regulatory role.The current study shows that IL mainly through the impact of the whole organism and/or local immune system mediated by the emergence of UC and UC's persistent and repeated attack on the refractory.In this paper,respectively, pro-inflammatory cytokines and anti-inflammatory cytokines in the pathogenesis of UC's research progress and the role of traditional Chinese medicine to control synthesis.
3.ICAM-1 in IBD inflammation in the process of expression and the role
Adhesion molecule(AM) is a class of cells and cell-mediated,cells and extracellular matrix in the role of intercellular adhesion,with a variety of biological functions of the membrane surface glycoprotein.Which endothelial cell adhesion molecule -1(ICAM-1) belong to immunoglobulin superfamily,in the IBD pathogenesis of attention in recent years.In this paper,there are Several aspects, ICAM-1 of the biological characteristics,In the role of inflammation,Expression in IBD and the role,Anti-cell adhesion molecule antibody therapy in IBD Research, Chinese medicine through the intervention treatment of ICAM-1 expression in rats UC Research.
The study in experiment
1.Content
Pharmacodynamic study:
①Separately from the UC rat model of TNBS in general on the performance of the growth rate of the impact of body weight,colon histopathology observed the effects of three KKLon experimental ulcerative colitis in rats.
②To observe anti-inflammatory and analgesic effects of KKL.Anti-inflammatory effect of KKL was investigated by mixed-croton oil-induced aruical swelling in mice and Plastic loop-induced granuloma.Analgesic effect of KKL was investigated by hot plate test and acetic acid writhing test in mice. Mechanism of immune:
①Xylene-induced ear swelling and carrageenan-induced paw swelling,rat peritoneal leukocyte migration observed the impact of delayed-type hypersensitivity of KKL.
②From serum IL-8 content,hemorheology,colonic mucosal NO content,NOS activity in the colon of ICAM-1 gene expression and the number of mesenteric lymph nodes and peripheral blood CD_4~+ CD_(25)~+ regulatory T cells,observed KKL the immune regulation role in experimental rats UC.
2.Methods
The healthy male Wister rats is divided 6 groups randomly,which is individually normal group,model group,3 Kuikeling treatment group included large dose group,medium and little dose group,SASP treatment group.The UC rats model is performed by TNBS/Alcohol Solution(100mg/kgTNBS+50%Alcohol Solution 0.25ml) enema.The all groups are given by pouring into stomach individually Chinese medicine,western medicine and 0.9%NaCl solution according to the equivalent of person to rats.It performs 1 times/day for 3 weeks.After 3 weeks,we collect blood and the tissue of colon of the rats.Then observe relevant target.Constituting acute inflammation model and pathological model of chronic granulomatous,then observe relevant target.Analgesic effect of KKL was investigated by hot plate test and acetic acid writhing test in mice.
3.Results
General conditions:The rats' general conditions of normal group and all treatment groups after 1 week's treatment are better than that of model group.
Observation by optical microscope:The structure of colon in normal group is clear and no inflammation.The structure of colon in model group show obvious inflammation and even forms severe ulcer.Treatment groups(including the KKL in each group,SASP group) there was some improvement in the degree of inflammation(P＜0.01,P＜0.05).
Anti-inflammatory effects:KKL can inhibit croton oil-induced ear swelling reaction in mice,inhibit murine peritoneal increased capillary permeability caused by Hac,reduce wet weight and dry weight of plastic ring granuloma in rats(P＜0.01, P＜0.05).
Analgesic effect:KKL can improve hot-plate pain threshold of rats,reduce the number of writhing of mice induced by acetic acid(P＜0.01,P＜0.05).
The impact of the delayed type hypersensitivity:KKL has a significant inhibitory effect for xylene-induced ear edema in mice,Carrageenan-induced paw swelling and intraperitoneal injection of sodium carboxymethyl cellulose in the abdominal cavity caused by travel of leukocyte accumulation(P＜0.01,P＜0.05).
Content of IL-8:Compared with normal group,model group,serum IL-8 level was significantly higher(P＜0.01);Compared with model group,the treatment groups,serum IL-8 levels decreased significantly(P＜0.01).
Content of NO and NOS:Compared with normal group,model group rats colonic mucosal NO content,NOS activity was significantly higher(P＜0.01); Compared with model group,the treatment group(including the KKL in each group, SASP group) colonic mucosal NO content,NOS activity significantly lower (P＜0.01).
Content of ICAM-1:Compared with normal group,model group,rat colon tissue ICAM-1 gene expression was significantly higher(P＜0.01),while the collapse of high-dose group KKL,SASP group than in model group decreased significantly (P＜0.01).
Hemorrheology Change:Compared with normal group,model rats blood viscosity,plasma viscosity and hematocrit were significantly higher(P＜0.01); Compared with model group,KKL can significantly reduce the rat whole blood viscosity,plasma viscosity and hematocrit(P＜0.01,P＜0.05).
CD_4~+ CD_(25)~+regulatory T cells:compared with normal group,the number of mesenteric lymph nodes and peripheral blood CD_4~+ CD_(25)~+regulatory T cells of model group significantly decreased(P＜0.01),while the KKL high,medium dose group, SASP group than in model group increased significantly(P＜0.01,P＜0.05).
3.Conclusions
The UC of rat model is succeeded by TNBS/alcohol solution(100mg/kgTNBS +50%Alcohol Solution 0.25ml) enema.The KKL,whose main effects is invigorating the spleen and removing humid,has a good therapeutic results to UC, which means weak spleen and stomach,hygrothermal intrinsic is one of fundamental pathogenesis of UC.KKL in the general status,pathological status,anti-inflammatory, analgesic,etc.show the advantages.The therapeutic results of KKL are associated with its effects which inhibit delayed type hypersensitivity,decrease the content of NO、NOS,the content of IL-8 and the expression of ICAM-1,improve the hemorheology and increase the number of CD_4~+ CD_(25)~+ regulatory T cells in rat model.So we make clear the partial mechanism of KKL to treat UC and exploit a new thinking of treating UC in TCM.
溃克灵(KKL)是在南京市鼓楼医院消化科多年临床经验基础上总结出的用于治疗UC的有效中药复方。我们认为脾虚是UC发病之本,湿热邪毒为致病之标,气滞血瘀贯穿始终,脾肾阳虚是本病主要转归和病情迁延不愈的重要因素。KKL具有健脾益气、清热祛湿、活血化瘀的功效,临床应用显示较好的疗效,无明显毒副作用。KKL先期实验研究已经证实,中药KKL对TNBS法灌肠复制模型大鼠结肠炎的发生具有一定预防保护作用,能明显减少大鼠结肠溃疡个数和面积,改善结肠粘膜炎症和水肿等病理变化,可能与下调CD4~+/CD8~+比值、抑制促炎因子IL-1β分泌和促进抗炎因子IL-10分泌等免疫调节机制有关。为了进一步研究溃克灵治疗溃疡性结肠炎药效及免疫机理,我们选择了溃克灵治疗溃疡性结肠炎药效及免疫机理研究,这一研究将使中医药治疗UC的机理研究深入到基因调控水平,并为开发高质量的抗UC中药新药打下坚实的基础,有重要的理论意义和广阔的应用前景。
本论文分上、下两篇对KKL治疗UC进行了理论和实验研究。
上篇理论研究:
1.中医学对溃疡性结肠炎的研究现状
对中医学关于UC的病名的认识、病因病机的认识及治疗现状进行了全面综述。并根据UC的主要临床表现,经严密剖析与推理,提出我们的观点:脾虚湿盛是UC发病的基本病机,贯穿UC的始终。
2.白介素在溃疡性结肠炎发病机制中的研究进展
白介素(IL)是细胞因子中最主要的具有多种生物活性的一组淋巴因子,并在免疫细胞的发育、分化、免疫应答及某些细胞的激活过程中有重要调节作用。目前研究表明IL主要通过影响机体整体和/或局部免疫系统的功能介导UC的产生,并与UC的迁延难愈和反复发作有关。本文分别对促炎细胞因子和抗炎细胞因子在UC发病机制中的研究进展及中药调控作用做以综述。
3.ICAM-1在IBD炎症过程中的表达及作用
粘附分子(AM)是一类介导细胞与细胞、细胞与细胞外基质间粘附作用的,具有多种生物功能的膜表面糖蛋白。其中内皮细胞黏附分子-1(ICAM-1)属于免疫球蛋白超家族,在IBD发病中的作用近年来受到关注。本文阐述了ICAM-1的生物学特性、在炎症中的作用、在IBD中的表达及作用、抗细胞粘附分子抗体在IBD治疗中的研究、中药通过干预ICAM-1表达治疗UC实验大鼠的研究等几个方面内容。
下篇实验研究:
1.研究内容
1.1溃克灵治疗溃疡性结肠炎主要药效学研究
①分别从溃克灵对TNBS法UC模型大鼠一般表现的影响,体重增长率的影响,结肠病理组织学的影响三方面观察溃克灵对实验性溃疡性结肠炎大鼠的影响;
②分别从溃克灵对巴豆油混合致炎剂所致小鼠耳廓肿胀的影响,对腹腔注射醋酸所致小鼠腹腔毛细血管通透性增高的影响,对大鼠塑料环肉芽肿的影响三方面观察溃克灵的抗炎作用;
③分别采用热板法测定溃克灵对小鼠痛阈值和对小鼠痛阈提高百分率的影响,醋酸扭体法测定溃克灵对小鼠扭体次数的影响观察溃克灵的镇痛作用。
1.2溃克灵治疗溃疡性结肠炎免疫机理研究
①分别从2.5二甲苯致耳肿胀,角叉菜胶致足肿胀,大鼠腹腔白细胞游走三方面观察溃克灵对迟发性超敏反应的影响;
②分别从溃克灵对TNBS法UC模型大鼠血清IL-8含量、血液流变学、结肠黏膜NO含量、NOS活性、结肠组织ICAM-1基因表达、外周血和肠系膜淋巴结CD_4~+CD_(25)~+调节性T细胞数量等几方面观察溃克灵对实验性UC大鼠的免疫调节作用。
2.主要研究方法
将健康Wisater大白鼠随机分成六组,即正常对照组、模型组、溃克灵大剂量组、溃克灵中剂量组、溃克灵小剂量组、柳氮磺胺吡啶组。采用TNBS/乙醇溶液(100mg/kgTNBS+50%的乙醇0.25ml)灌肠法造模。按人与动物等效剂量,分别对各组大鼠进行中、西药及生理盐水灌胃,每日一次,连续三周。第3周末处死大鼠,采集血液与结肠组织标本,检测相关指标;急性炎症模型、慢性肉芽肿病理模型建立,检测相关指标;热板法和扭体法观察溃克灵镇痛作用。
2.结果
一般状态:正常组大鼠明显优于模型组大鼠,治疗组用药1周左右能明显改善模型组大鼠的状态。
光镜观察:正常组结肠各层结构清晰,无炎性改变。模型组结肠粘膜炎症显著,重者有严重溃疡形成。各治疗组(包括KKL各组、SASP组)炎症程度均有改善(P＜0.01,P＜0.05)。
抗炎作用:KKL各剂量组均能抑制巴豆油所致小鼠耳廓肿胀反应,能抑制HAc所引起小鼠腹腔毛细血管通透性的增高,降低大鼠塑料环肉芽肿湿重和干重,有抗肉芽组织形成作用(P＜0.01,P＜0.05)。
镇痛作用:KKL各剂量组均能提高热板法大鼠痛阈值,尤其在给药后1h效果最明显,KKL高、中剂量能明显减少醋酸所致小鼠扭体次数,(P＜0.01,P＜0.05)。
对迟发型变态反应的影响:KKL各剂量组均对二甲苯致小鼠耳廓肿胀有极显著的抑制作用,对角叉菜胶致足肿胀有极显著的抑制作用,对腹腔注射羧甲基纤维素钠引起的白细胞在腹腔游出、聚集有显著抑制作用(P＜0.01,P＜0.05)。
血清IL-8含量:与正常组相比,模型组大鼠血清IL-8水平显著增高(P＜0.01);与模型组相比,各治疗组血清IL-8水平显著降低(P＜0.01)。
结肠黏膜NO含量、NOS活性:与正常组相比,模型组大鼠结肠黏膜NO含量、NOS活性显著增高(P＜0.01);与模型组相比,各治疗组(包括KKL各组、SASP组)结肠黏膜NO含量、NOS活性显著降低(P均＜0.01)。
结肠组织ICAM-1基因表达:与正常组相比,模型组大鼠结肠组织中ICAM-1基因表达显著增高(P＜0.01),而溃克灵大剂量组、SASP组较模型组明显降低(P＜0.01)。
血液流变学变化:与正常组相比,模型组大鼠全血粘度、血浆粘度和红细胞压积均明显增高(P＜0.01)。与模型组相比,溃克灵三个剂量组均能显著降低造模大鼠全血粘度、血浆粘度和红细胞压积(P＜0.01,P＜0.05)。
CD_4~+ CD_(25)~+调节性T细胞:与正常组相比,模型组外周血和肠系膜淋巴结CD_4~+ CD_(25)~+调节性T细胞数量明显下降(P＜0.01),而溃克灵高、中剂量组、SASP组较模型组明显增高(P＜0.01,P＜0.05)。
3.结论
采用TNBS/乙醇溶液(100mg/kgTNBS+50%的乙醇0.25ml)灌肠法复制UC大鼠模型成功,完全符合实验要求。以健脾祛湿为主要功用的KKL对实验性UC大鼠治疗效果肯定,不论在一般状态、病理状态、抗炎、镇痛等方面均显示出中医药治疗溃疡性结肠炎具有较大优势,进而说明脾虚湿盛是UC发病的基本病机,其疗效的产生与该方能抑制迟发型变态反应、降低结肠黏膜NO含量、NOS活性、下调炎性细胞因子IL-8、下调细胞间粘附分子ICAM-1的表达、改善造模大鼠血液流变学及提高CD_4~+ CD_(25)~+调节性T细胞数量有关,明确了KKL治疗UC的部分作用机制,开拓了中医药治疗UC的新思路。
Ulcerative colitis(UC) is an inflammatory bowel disease of the rectal and colonic mucosa.The aetiology of UC remains unknown.UC seems to result from a complex series of interactions between susceptibility genes,the environment and the immune system.An involvement of the immune system plays an important role in the pathogenesis of UC.With the fast development of immunology,molecular biology and investigation of cytokines,adherence factor,the mechanism of UC has been revealed step by step.Therapeutic effect of traditional Chinese medicine(TCM) on UC was similar to than of Western medicine.But the defect of Western medicine such as easy recurrence,toxicity and side effects were seldom found in using TCM. The prospect of utilization and development of TCM is cheerful.The key point of investigation on treating UC with TCM was empirical studied on mechanism of action.
Kuikeling decoction(KKL) was summarized for the treatment of UC effective Chinese herbal compound in Gastro enterology of Nanjing Drum Tower Hospital on the basis years of clinical experience.We consider spleen deficiency are the root of UC,and the fire,humid,food stasis are the tip of UC.The therapeutic principle of the decoction was clearing away heat,removing humid,invigorating the spleen and activating blood.It showed affirmative therapeutic effect on patients without obvious toxicity and side effects.In the past investigation,effect of KKL on UC model rats induced by TNBS was observed.It was observed that the number and area of ulcer model rats were significantly reduced with the administration of KKL.Pathological changes such as inflammatory cell infiltration and edema were improved.It showed affirmative curative effect of KKL on treating UC model rats induced by TNBS.In order to further study the treatment of ulcerative colitis KKL efficacy and immune mechanism,we have chosen the ulcer treatment of ulcerative colitis KKL efficacy and mechanism of immunity.This research will enable the Chinese medicine treatment of UC into the mechanism of gene regulation level,and for the development of high-quality anti-UC Chinese medicine and lay a solid foundation, there are important theoretical significance and wide application prospects.
In this paper,upper and lower two pairs of ulcer treatment kling UC theoretical and experimental studies.
The study in theory
1.The status of UC in Traditional Chinese medicine(TCM)
It is rounded up thoroughly about the knowledge of name of disease of UC, cause of disease and pathogenesis and the status of treatment in TCM.We put up with our viewpoint that is the weak spleen and stomach,hygrothermal intrinsic is the fundamental pathogenesis of UC and has during UC by the main clinical manifestation.
2.Interleukin in the pathogenesis of ulcerative colitis Research Progress
Interleukin(IL) is the most important cytokine with multiple biological activity of a group of lymphokines and immune cells in the development,differentiation, immune response and certain cells in the activation process as an important regulatory role.The current study shows that IL mainly through the impact of the whole organism and/or local immune system mediated by the emergence of UC and UC's persistent and repeated attack on the refractory.In this paper,respectively, pro-inflammatory cytokines and anti-inflammatory cytokines in the pathogenesis of UC's research progress and the role of traditional Chinese medicine to control synthesis.
3.ICAM-1 in IBD inflammation in the process of expression and the role
Adhesion molecule(AM) is a class of cells and cell-mediated,cells and extracellular matrix in the role of intercellular adhesion,with a variety of biological functions of the membrane surface glycoprotein.Which endothelial cell adhesion molecule -1(ICAM-1) belong to immunoglobulin superfamily,in the IBD pathogenesis of attention in recent years.In this paper,there are Several aspects, ICAM-1 of the biological characteristics,In the role of inflammation,Expression in IBD and the role,Anti-cell adhesion molecule antibody therapy in IBD Research, Chinese medicine through the intervention treatment of ICAM-1 expression in rats UC Research.
The study in experiment
1.Content
Pharmacodynamic study:
①Separately from the UC rat model of TNBS in general on the performance of the growth rate of the impact of body weight,colon histopathology observed the effects of three KKLon experimental ulcerative colitis in rats.
②To observe anti-inflammatory and analgesic effects of KKL.Anti-inflammatory effect of KKL was investigated by mixed-croton oil-induced aruical swelling in mice and Plastic loop-induced granuloma.Analgesic effect of KKL was investigated by hot plate test and acetic acid writhing test in mice. Mechanism of immune:
①Xylene-induced ear swelling and carrageenan-induced paw swelling,rat peritoneal leukocyte migration observed the impact of delayed-type hypersensitivity of KKL.
②From serum IL-8 content,hemorheology,colonic mucosal NO content,NOS activity in the colon of ICAM-1 gene expression and the number of mesenteric lymph nodes and peripheral blood CD_4~+ CD_(25)~+ regulatory T cells,observed KKL the immune regulation role in experimental rats UC.
2.Methods
The healthy male Wister rats is divided 6 groups randomly,which is individually normal group,model group,3 Kuikeling treatment group included large dose group,medium and little dose group,SASP treatment group.The UC rats model is performed by TNBS/Alcohol Solution(100mg/kgTNBS+50%Alcohol Solution 0.25ml) enema.The all groups are given by pouring into stomach individually Chinese medicine,western medicine and 0.9%NaCl solution according to the equivalent of person to rats.It performs 1 times/day for 3 weeks.After 3 weeks,we collect blood and the tissue of colon of the rats.Then observe relevant target.Constituting acute inflammation model and pathological model of chronic granulomatous,then observe relevant target.Analgesic effect of KKL was investigated by hot plate test and acetic acid writhing test in mice.
3.Results
General conditions:The rats' general conditions of normal group and all treatment groups after 1 week's treatment are better than that of model group.
Observation by optical microscope:The structure of colon in normal group is clear and no inflammation.The structure of colon in model group show obvious inflammation and even forms severe ulcer.Treatment groups(including the KKL in each group,SASP group) there was some improvement in the degree of inflammation(P＜0.01,P＜0.05).
Anti-inflammatory effects:KKL can inhibit croton oil-induced ear swelling reaction in mice,inhibit murine peritoneal increased capillary permeability caused by Hac,reduce wet weight and dry weight of plastic ring granuloma in rats(P＜0.01, P＜0.05).
Analgesic effect:KKL can improve hot-plate pain threshold of rats,reduce the number of writhing of mice induced by acetic acid(P＜0.01,P＜0.05).
The impact of the delayed type hypersensitivity:KKL has a significant inhibitory effect for xylene-induced ear edema in mice,Carrageenan-induced paw swelling and intraperitoneal injection of sodium carboxymethyl cellulose in the abdominal cavity caused by travel of leukocyte accumulation(P＜0.01,P＜0.05).
Content of IL-8:Compared with normal group,model group,serum IL-8 level was significantly higher(P＜0.01);Compared with model group,the treatment groups,serum IL-8 levels decreased significantly(P＜0.01).
Content of NO and NOS:Compared with normal group,model group rats colonic mucosal NO content,NOS activity was significantly higher(P＜0.01); Compared with model group,the treatment group(including the KKL in each group, SASP group) colonic mucosal NO content,NOS activity significantly lower (P＜0.01).
Content of ICAM-1:Compared with normal group,model group,rat colon tissue ICAM-1 gene expression was significantly higher(P＜0.01),while the collapse of high-dose group KKL,SASP group than in model group decreased significantly (P＜0.01).
Hemorrheology Change:Compared with normal group,model rats blood viscosity,plasma viscosity and hematocrit were significantly higher(P＜0.01); Compared with model group,KKL can significantly reduce the rat whole blood viscosity,plasma viscosity and hematocrit(P＜0.01,P＜0.05).
CD_4~+ CD_(25)~+regulatory T cells:compared with normal group,the number of mesenteric lymph nodes and peripheral blood CD_4~+ CD_(25)~+regulatory T cells of model group significantly decreased(P＜0.01),while the KKL high,medium dose group, SASP group than in model group increased significantly(P＜0.01,P＜0.05).
3.Conclusions
The UC of rat model is succeeded by TNBS/alcohol solution(100mg/kgTNBS +50%Alcohol Solution 0.25ml) enema.The KKL,whose main effects is invigorating the spleen and removing humid,has a good therapeutic results to UC, which means weak spleen and stomach,hygrothermal intrinsic is one of fundamental pathogenesis of UC.KKL in the general status,pathological status,anti-inflammatory, analgesic,etc.show the advantages.The therapeutic results of KKL are associated with its effects which inhibit delayed type hypersensitivity,decrease the content of NO、NOS,the content of IL-8 and the expression of ICAM-1,improve the hemorheology and increase the number of CD_4~+ CD_(25)~+ regulatory T cells in rat model.So we make clear the partial mechanism of KKL to treat UC and exploit a new thinking of treating UC in TCM.
引文
[1]延卫东,何琰,陈延.余绍源教授治疗UC经验[J].河南中医,2006,26(6):17.
[2]罗文纪,陈波.王福仁主任医师治疗溃疡性结肠炎临床经验[J].福建中医药,2006,37(2):22-23.
[3]吴中秋,赵志国,王俊月,等.辨证治疗UC的体会[J].河北中医药学报,2006,21(2):18-19.
[4]戴宝林.UC病因病机探讨及辨证体会[J].天津中医学院学报,2001,20(2):37-38.
[5]焦君良等,从痈论治溃疡性结肠炎初探[J].中国中西医结合脾胃杂志,2000,8(2):100-101
[6]姚小丽,姚雪芬,邹亚君,等辨证论治和施护相结合治疗溃疡性结肠炎[J]浙江中医学院学报,2005,29(2):41-42
[6]曹众毅,邬建平,平衡中焦法治疗溃疡性结肠炎的体会[J].中国医药学报,2003,18(10):617
[7]章浩军,六经辨证治疗溃疡性结肠炎[J].福建中医学院学报,2003(13)2:19
[8]侯高.止泻三合方治疗慢性UC126例[J].新中医,2006,38(1):80.
[9]温如丰.疏肝活血健脾法治疗慢性UC68例[J].陕西中医,2003,24(1):57.
[10]周奚钟.中药治疗慢性UC83例[J].江苏中医,2006,27(4):38.
[11]丁建华.除湿活血汤治疗慢性UC50例[J].中医研究,2006,19(10):37.
[12]杨万里,张晓燕.溃结灵汤治疗慢性UC60例[J].陕西中医,2003,24(7):625.
[13]李小平.中西医结合治疗慢性UC85例总结[J].湖南中医杂志,2006,22(5):20.
[14]傅慧琴,倪士昌.中西医结合治疗UC46例[J].浙江临 床医学,2001,3(8):559.
[15]章红.健脾止泻方保留灌肠治疗慢性UC38例疗效观察[J].河北中医,2006,28(5):336-337.
[16]何长义,王佐军.辨证治疗UC118例[J].河北中医,2005,27(4):267-268.
[17]吕迎春,宋怀春,王玉新,等.中医辨证分型治疗慢性UC37例[J].现代中西医结合杂志,2005,14(8):1047.
[18]张正荣.中西医结合治疗慢性UC36例[J].中国临床医生,2000,28(6):371.
[19]姚小丽,姚雪花,邬亚君,等.辨证论治和施护相结合治疗UC[J].浙江中医学院学报,2005,29(2):41-42.
[20]谭远忠,姜锦林.辨证与辨病治疗UC40例临床观察[J].时珍国医国药,2000,11(3): 261-261.
[21]焦君良,要丽英,孟元勋,等.溃结康胶囊治疗溃疡性结肠炎的临床研究[J].中国中西医结合脾胃杂志,1999,7(3):174
[22]闫惠俊,龙致贤,常章富,韩长柏.中医药治疗溃疡性结肠炎研究进展.中成药[J],2001(23)9:684[
23]于明环.灌肠散保留灌肠治疗UC141例[J].实用中医内科杂志,200418(2):9.
[24]陈庆华.愈溃汤保留灌肠治疗UC[J].山西中医,2004,20(2):43.
[25]黄瑗凤,刘云艳.中药保留灌肠治疗UC68例[J].中国中医药科技,2005,12(1):46.
[26]迟莉丽,隗继武.运用安肠愈疡汤口服合生肌散灌肠治疗UC的临床研究[J].山东中医药大学学报,2004,28(6):787-788.
[27]冯其斌,陈翠萍.中医综合疗法治疗慢性UC59例疗效观察[J].新中医,2003,35(1):26-27.
[28]张府平.中医药治疗UC40例疗效观察[J].湖南中医药导报,2003,9(1):34.
[29]杨顺益.针灸治疗UC的临床观察[J].上海针灸杂志,2001,20(1):17.
[30]杨振辉,张悦,孙英霞.针刺夹脊穴配合梅花针叩刺治疗UC疗效观察[J].中国针灸,2003,23(3):141.
[31]张勤良,刘景峰.针刺夹脊穴配合背俞穴治疗UC95例[J].辽宁中医杂志,2003,30(8):679.
[32]王会珍.针灸综合疗法治疗UC64例[J].上海针灸杂志,2005,24(10):31.
[33]吕明,刘晓艳.推拿三步九法结合针灸治疗慢性UC46例[J].辽宁中医杂志,2005,32(9):951.
[34]王松梅,张立群,孙建.针灸治疗UC的临床效果[J].实用医药杂志,2003,20(2):135.
[35]于荣.温针百会治疗UC[J].浙江中医杂志,1992,(11):522.
[36]李玉琴,高晓明,张智利.穴位埋线治疗慢性结肠炎1190例疗效分析[J].针灸临床杂志,1997,(2):29.
[37]欧阳建东,李明,高静,等.中药栓剂治疗UC的临床研究[J].中国肛肠病杂志,2000,20(7):19.
[38]王璐,李克迪,谭华.中药脐疗辅助治疗UC的临床研究[J].中国肛肠病杂志,2003, 23(7):9.
[39]黄辉.中药灌肠结合肛肠内热磁疗法治疗溃疡性结肠炎40例[J].中国肛肠病杂志,2002,22(7):26.
[1]桑力轩,刘汉立,姜敏.溃疡性结肠炎发病机制研究进展[J].世界华人消化杂志,2007(15):2249-2254.
[2]口锁堂,吴焕淦,施达仁.白介素与溃疡性结肠炎[J].世界华人消化杂志,2006(14):405-411.
[3]崔玉芳,徐菡,安小霞,等.T辅助细胞亚群与炎症性肠病的关系[J].世界华人消化杂 志,2005(13):2464-2468.
[4]庞艳华,郑长青.Th1/Th2细胞亚群与炎症性肠病的关系[J].世界华人消化杂志,2004(12):1922-1924.
[5]张文俊,许国铭,李兆申,等.血清白细胞介素-1B与溃疡性结肠炎的关系[J].第二军医大学学报,2002;23:1345-1347.
[6]Ashwood Harvey R,Veriee T,Wolstencroft R,Thompson RP,Powell JJ.Functional interactions between mucosal IL-1,IL-ra and TGF-beta l in ulcerative colitis[J].Inflamm Res 2004(53):53-59
[7]石敏,吴曙光.白细胞介素1a对多形核白细胞凋亡的抑制作用[J].中国药理学通报,2000(16):455-458
[8]Wu HG,Liu HR,Zhao C Zhan g Wu xF,ZhouS,Shi Y,Liu M.Study on differentially expressed genes of ulcerative colitis in the rat treated by Herbs-partitioned moxibustion[J].Zhong-guo ZheH iu,2005(25):359-365
[9]Sawa Y,Oshitani N,Adachi K,Higuchi k,M at-sumoto T,Arakawa T.Comprehensive analysis of intestinal cytokine m essenger RN A profile by real-tilDe quantitative polvmerase chain reaction in patients with Inflammatory bowel disease[J],Intf MofMed,2003(11):175
[10]钱立平,徐三荣,林庚金,丁伟群.溃疡性结肠炎发病中白介素水平的变化[J].复旦学报(医学科学版)2001(28):330-335
[11]Mittal RD,Bid HK.Ghoshal UC IL-1 receptor antagonist(IL-1Ra)gene polymorphism in patients with inflammatory bowel disease in India[J].Stand 1 Gastroenterol,2005(40):827-831
[12]LudwiczekO,Vannier E,Borggraefe I,KaserA,Siegmund B,Dinarello CA,Tilg H Imbalance betw een interleukin-1 agonists an d an tagonists.,relationship to severity of inflammatory bowel disease[J],ain Exp Immun,2004(138):323-329
[13]W itkin SS,Gerber S,Ledger W,.Influence of interleukin-1 receptor an tagonist gene polymorphism on disease[J].Ctin Infect Dis 2002(34):204-209
[14]Ishizuka Sugimura HommaT,MatsuzawaJ,MochizukiT,KobayashiM,Suzuki K,Otsuka K,Tashiro K,Yamaguchi O,Asakura H.Infl uence of interleukin-10 on the interleukin-1receptor an tagonist/interleukin-1 beta ratio in the colonic mucosa of ulcerative coiltis[J].Diestion 2001(63):22-27
[15]张涛,谢建群.清肠栓对溃疡性结肠炎大鼠血清白介素影响的研究[J].辽宁中医药大 学学报,2006;8(4):50-52.
[16]王晓梅,郊世江,李静,等.溃结宁合剂对溃疡性结肠炎大鼠IL-1β和L1-4的影响[J].山西中医学院学报,2006(7):18-20.
[17]李楠,王雪明,吴凯,等.复方血竭对溃疡性结肠炎模型大鼠细胞因子的调节作用[J].中国中西医结合消化杂志,2007(15):377-379.
[18]朱萱萱,沈洪,施荣山,等.肠安胶囊治疗大鼠免疫性溃疡性结肠炎的实验研究[J].中国中医药科技,2002;9:19-21.
[19]邹阳,王兴友,杨孝芳.溃疡性结肠炎大鼠IL-2、CD44、CD54的实验研究[J].江西医学检验,2002:20:281-282,276.
[20]古学文.溃疡性结肠炎患者血清IL-2及slL-2R浓度变化的研究[J].临床和实验医学杂志,2003,2:153-155.
[21]Van Assche G,Dalle I,Nom an M,et al.A pilot study onthe use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis[J].Am J Gastroenterol 2003:98:375-376.
[22]李桂贤,黄勇华,唐梅文,等.加味柴芍六君颗粒对实验性溃疡性结肠炎大鼠T淋巴细胞亚群及白介素-2的影响[J].广西中医药,2007:30(4):51-53.
[23]段永强,程畅和,成映霞,等.痛泻二草方对溃疡性结肠炎模型大鼠血清IL-2含量及肠黏膜NO含量、NOS活性的影响[J].中国中医药信息杂志,2007;14:34-36.
[24]葛相栓,吴正祥,吴强,等.垂盆草对实验性结肠炎的保护作用及其机制研究[J].中国中西医结合消化杂志2007:15:391-394.
[25]Kitamura 1(,Nakamoto Y,Kan eko S,Mukaida N Pivotal roles of interleukin-6 in transmural inflammation in murine T cell transfer colitis[J].Leukoc Bio,2004:76:1111-1117
[26]邓长生.溃疡性结肠炎患者白细胞介素-6活性研究.中华消化杂志,2001:21:223-225
[27]Raddatz D,Bockemuhl M,Ramadori G.Quantitative measurement of cytokine mRNA in inflammatory bowel disease:relation to clinical and andoscopic activity and outcome[J].Eur,Gastroentero Hepatof 2005:17:547-557
[28]贾百灵,侯晓华.白细胞介素-6与溃疡性结肠炎的关系[J].胃肠病学和肝病学杂志2004;13:217-221.
[29]王伟宁,张熙纯,刘丽.活动期溃疡性结肠炎发病机制的免疫学探讨[J].中国现代医学杂志,2003:13:74-76.
[30]Daig R,Rogler G,Aschenbrenner E,et al.Human intestinal epithelial cells secrete interleukin-1 receptor antagonist and interleukin-8 but not interleukin-1 or imerleukin-6[J].Gut 2000;46:350-358
[31]连建学,刘洁,李洛平,等.结肠安胶囊对实验性溃疡性结肠炎大鼠IL-6、SOD及MDA 表达的影响[J].陕西中医,2006;27:240-241.
[32]祝斌,徐军发,李巧勤,等.阴阳平衡散对溃疡性结肠炎患者血清细胞因子的影响[J].实用全科医学,2007;5:578-579.
[33]吕永慧,胡品津,陈文红,等.中药肠炎清治疗小鼠葡聚糖硫酸钠所致结肠炎的机制[J].世界华人消化杂志,2006;14:1283-1287.
[34]王伟宁,张熙纯,刘丽.活动期溃疡性结肠炎发病机制的免疫学探讨[J].中国现代医学杂志,2003;13:74-78
[35]Imada A,Ina K,Shimada M,Yokoyama T,Yokoyama Y Nishio Y Yamaguchi T Ando T KusugamiK.Coordinate upregulation of interleukin-8 and growth-related gene product-alpha is present in the colonic mucosa of inflammatory bowel[J].Scand 7 Gastroenterol,2001,36:854-864
[36]Tsukada Y,Nakamura T,Iimura M,Iizuka BEHayashi N.Cytokine profile in colonic mucosa of ulcerative co～fis correlates with disease acfivity and response to gran ulocytapheresis[J].Am J Gastroentero,2002;97:2820-2828
[37]屠振兴,李兆申,许国铭,龚燕芳,张文俊.血清白细胞介素-8与溃疡性结肠炎的关系[J].胃肠病学,2002;7:277-279
[38]AkazawaA,Sakaidal,HigakiS,etal.Increased expression of tumor necrosisfactor-alpha messenger RNA in the intestinal mucosa of inflammatory bowel disease,Particularly in patients With disease in the inactive phase[J].JGastroenterol,2002,37(5):345-353.
[39]范恒,邱明义,杨胜兰,梅家俊,沈关心,刘松林.理肠方对溃疡性结肠炎大鼠观察[J].中国中西医结合杂志,2004;12:155
[40]Ishiguro Y.M ucosal proinflam matory cytokine production correlates with endoscopic activity of ulcerafive colitis[J].Gastroenterol,1999,34:66-74
[41]范恒,邱明义,梅家俊,沈关心,刘松林.理肠方对溃疡性结肠炎大鼠组织细胞因子TNF-、IL-6、IL-8 IL-10的影响[J].中医药学刊,2004;22:1624-1628
[42]吴限.结肠灵治疗溃疡性结肠炎的机制研究[J].中国全科医学,2007,10:9699-971.
[43]王新月,杨莉莉,王雪茜,等.溃结饮不同给药途径对溃疡性结肠炎大鼠前炎性细胞因子表达的影响[J].中国中西医结合消化杂志,2006:14:351-354.
[44]郭雁冰,王新月,林燕.I L-8与溃疡性结肠炎复发的关系及中药抗复发的研究[J].新中医,2008,40(2):52-53.
[45]董恩钰,王晓娣.白介素-17在溃疡性结肠炎表达的研究[J].中华消化杂志,2001:21:673-877
[46]Fujino S Andoh A Bamba S Ogawa AHata KAraki Y,Bamba T,Fujiyama Y.Increased expression of interleukin 17 in inflammatory bowel disease[J].Gut 2003:52:65-70
[47]Nielsen OH,Kirman I,Rudiger N,Hendell,VainerB.Upregulation of interleukin-12 and-17in active inflammatory bowel disease[J].Scand,Gastroenterol,2003:38:180-185
[48]Okamura H,Tsutsi H,Komatsu T,Yutsudo M,Hakura A,Tanimoto T,Torigoe K,Okura T,Nukada Y.Ha～ofi K.Cloning of a new cytokine th at induces IFN-gam ma production byT cells[J].Nature,1995:378:88-91
[49]张丁丁,游自立,杨明清,等.溃疡性结肠炎患者血清IL-18的变化及意义[J].现代中西医结合杂志,2002;11:586-588.
[50]郭晓东,关庆.增加味四逆散对溃疡性结肠炎肝郁大鼠模型血清IL-4、IL-10的影响研究[J].中医药学刊,2004,22:659-662
[51]丁晓刚.黄芩汤有效成分配方对大鼠实验性溃疡性结肠炎的免疫调节作用[J].中医药学刊,2003:21:126.127
[52]Ten Hove T The Olie F Berkhout M Bruggeman JP,Vyth-Dreese FA,Slors JF,Van Deventer SJ,TVelde AA.Expression of CI)45RB functionally distinguishes intestinal T lymphocytes in -ulflarnmatory bowel disease[J].Leukoc Biof,2004,75:1010-1015
[53]Rermick DM,Fort MM.Lessons from genetically engineered anim al m odels.Ⅻ.1L-10-deficient(IL-10mice and intestinal inflammation[J].Am,Physiol Gastrointest Liver Physiol 2000,278:G829.G833
[54]Bene L Sapi Z Bajtai A.Buzas.Szentmihalyi.Arato A,Tulassay Z,Falus A.Partial protection against dextran sodium sulphate induced colitis in histam ine—deficient,histidine decarboxylase knockout mice[J].Pediatr Gastroenterol Nutr,2004,39:171-176
[55]霍丽娼,赵和平.实验性溃疡性结肠炎大鼠模型的研究[J].山西医科大学学报,2004,35:467-470
[56]Li M C,He SH.IL-10 and its related cytokines for treatment of inflammatory bowel disease[J].World,Gastroenterol,2004,10:620-625
[57]董文毅,胡刚正,郑长青.补脾清肠活血汤对溃疡性结肠炎患者淋巴细胞功能的影响[J].世界华人消化杂志,2006,14:1124-1127.
[58]Fuss II,Heller F,Boirivant M,Leon F,Yoshida M,Fichtner-Feigl s Yang Z.Exley M Kitani.Blum-berg RS,Marmon P,Strober W.Nonclassical CDldrestricted NK T cells that produce IL.13 characterize an atypical Th2 response in ulcerative colitis[J].Jclin Invest 2004,113:1490-1497
[59]Heller F,Florian P,B0iars C Richter J,Christ M,Hillenbran d B,Mankertz J,Gitter Burgel N,Fromm M,Zeitz M,Fuss I,Strober W,Schulzke ID.Interleu-kin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial fightjunctions,apoptosis,and cell restitution[J].GastroenteroloyoI 2005,129:550-564
[60]Targan SR.Karp LC.Defects in mucosal imm unity leading to ulcerative colitis[J].ImmunolRev,2005,206:296-305
[61]Lugering N,Kucharzik T,Kraft M,Winde G,Sorg C Stoll R,Domschke W.Interleukin IL-13 and IL-4 are potent inhibitors of IL-8 secretion by human intestinal epithelial cells[J].Dig Dis Sci,1999,44:649-655
[62]Vainer B,Nielsen oH,Hendel I,Horn T,Kirman I.Colonic expression an d synthesis of interleukin 13 and interleukin 15 in inflam matory bowel disease[J].Cvtokine,2000,12:1531-1536
[63]周字,叶文桃,麦海妍,郭汉城,王翠霞.白介素13和一氧化氮在溃疡性结肠炎的作用及意义[J].胃肠病学和肝病学杂志,2004,13:319-322
[1]闷萍,乐进秋,江汉.细胞粘附分子ICAM-Ⅰ在慢性牙周炎牙龈组织中自细胞的表达[J].广东牙病防治,2003;11(1):18-19.
[2]MaliziaG,CalabreseA,CottoneM,etal.Gastroenterology,1991,100(1):150-156
[3]费保莹,邓长生,朱尤庆.细胞粘附分子与炎症性肠病[J].国外医学:消化系疾病分册,1999;19(1):15-17.
[4]NieisenOH,BrynskovJ.VainerBDigDisSei,1996,41(9):1780-1785
[5]陈志贵,等.炎性肠病研究的展望[J].美国医学会杂志:中文版,2002;21(2):72.
[6]MaliziaG,CalabreseA,CottoneM,etal.Expressionofleukocyteadhesionmoleculesbymucosalmo nonuclearphagocytesininflammatoryboweldisease[J].Gastroenterology,1991,100:150
[7]施茵,刘慧荣,龚烨靓等.针药结合对大鼠溃疡性结肠炎TNF-a、ICAM-1基因表达的影响[J].实用中西医结合临床,2003;3(5):1-3.
[8]牛凤丽,郑萍,刘文忠,施尧.葡聚糖硫酸钠诱导大鼠结肠炎发病机制的研究[J].胃肠病学,2003:008(005).283-286.
[9]BendjelloulF.Rossmann P,MalyP.MandysV,JirkovskaM,Prokesova L.Tlaskalova Hogenova H.Detection ofICAM-ldeficient and wildtype m ice:an im munohistochemical study[J].Histochem J.2000,32:703-709.
[10]BendijelloulF,MalyP.MandysV,JirkovskaM,ProkesovaL,Tuckova L,TlaskalovaHogenovaHIntercellular dhesionmolecule-1(ICAM-1) deficiency protects mice against severe forms of xperimentally induced colitis[J].Clin Exp Im munol,2000;119:57-63.
[11]Mori N,Horie Y,Gerritsen ME,et al.Anti-inflammatory drugs and endothelial cell adhesion molecule expression in murine vascular beds[J].Gut,1999,44(2):186-195
[12]江学良,权启镇,孙自勤,等.糖皮质激素对重度溃疡性结肠炎患者淋巴细胞粘附分子表达的影响[J].中国危重病急救医学,1998,10(6):366
[13]Wittig B,Seiter S,Schmidt DS,et al.CD44 variant isoforms on blood leukocytes in chronic inflammatory bowel disease and other systemic autoimmune diseases[J].Lab Invest,1999,79(6):747-759
[14]CartyE,Macey M,Rampton DS.Inhibition of platelet activation by 5-aminosalicylic acid in inflammatory bowel disease[J].Aliment Pharmacol Ther,2000,14(9):1169-1179
[15]Fagerstam JP,Whiss PA,Strom M,et al.Expression of platelet P-selectin and ditection of soluble P-selectin,NPY and RANTES in patients with inflammatory bowel disease[J].Inflamm Res,2000,49(9):466-472
[16]Soriano A,Salas A,SalasA,etal.VCAM-1,but not ICAM-1 or MadCAM-1,immunoblockade ameliorates DSS-induced colitis in mice[J].Lab Invest,2000,80(10):1541-1551
[17]Taniguchi T.T sukada H.Kodam a M,Fukuda K,Saito T,M iyasaka M.Seino Y.Effects ofthe anti-ICAM-1 monocIonalantibody on dextrsm sodium sulphate-induced colitisin rats[J].JGastroenterolHepatol,1998;13:945-949.
[18]Wong PY etal.J Pharmacol Exp Ther,1995;274(1):475-480.
[19]杜群,李红,王汝俊等,溃结灵对溃疡性结肠炎大鼠结肠黏膜ICAM-1基因表达的作用[J].广州中医药大学学报,2008:25(3):229-232
[20]施茵,刘慧荣,龚烨靓,等.针药结合对大鼠溃疡性结肠炎TNF-a、ICAM-1基因表达的影响[J].实用中西医结合临床,2003,3(5):1.
[21]陈友琴,甘华田,欧阳钦,等.抗炎药物对溃疡性结肠炎患者肠黏膜组织NF-KB的活化和细胞粘附分子表达的影响[J].生物医学工程学杂志,2004,21(5):732.
[22]郑红斌,胡鸿毅,马贵同,清肠栓对溃疡性结肠炎实验大鼠ICAM-1表达的影响[J]. 浙江中医学院学报,2004,28(6):44-46
[23]赵晓霞,郭胜,李宝鹤等,芍药汤对溃疡性结肠炎大鼠ICAM-1、TNF-a、IL-10影响的实验研究[J].中国中医药科技,2008,15(3):174-175
[1]中华医学会消化病学分会炎症性肠病协作组.对我国炎症性肠病诊断治疗规范的共识意见[J].胃肠病学,2007,12(8):488-495.
[2]李桂珍,江必武,胡伟,等.猴头菌提取物颗粒治疗轻中度溃疡性结肠炎80例疗效观察[J].临床消化病杂志,2007,19(2):113-114.
[3]于成功,徐肇敏,祝其凯,等.猴头菌对实验大鼠胃粘膜保护作用的研究[J].胃肠病学,1999,4(2):93-96.
[4]王贤蕙,范秀容.猴头菌多糖对T淋巴细胞的调节作用.中国实验临床免疫学杂志,1990,2(4):40-43.
[5]许立,倪正,方泰惠,等.苍术胶囊抗炎免疫作用研究[J].陕西中医,2005,26(7):719-721.
[6]李曼玲,范莉,冯伟红,等.苍术的化学药理研究进展[J].中国中医药信息杂志,2002,11(9):79-82.
[7]朱自平,张明发,沈雅琴,等.厚朴对消化系统的药理作用[J].中国中药杂志,1997,22(11):686-688.
[8]谭永红,王诗华,梁容梅.中药半枝莲的研究进展[J].西南国防医药,2002,12(2):152-153.
[9]龚黎,于成功,杨珺.中药预处理对结肠炎模型大鼠的免疫调节效应[J].胃肠病学,2008,13(6):364-367.
[10]Morris GP,Beck PL,Herridge MS,et al.Hapten induced model of chronic inflannation and ulceration in the rat colon[J].Gastroenterology,1989,96:795
[11]Little JR,Eisen HN.Preparation and characterization of antibodies specific for the 2,4,6-trinitrophenyl group[J].Biochemistry,1996;5:3385-3395
[12]Fidler JM.Induction of hapten-specific immunological toleranct and immunity in Blymphocyes Ⅶ.correlation between trinitrobenzenesulfonic acid administration,serum trinitrophenyl content and level of tolerance[J].Cell Immunal,1985;94:285-291
[13]朱峰,钱家鸣,潘国宗.细胞免疫反应性炎症性肠病动物模型的建立[J].中国医学科学院学报,1998,20(4):271-278
[14]郑礼,高振强,王淑仙.大鼠溃疡性结肠炎模型的实验研究[J].中国药理学通,199,14(4):3706.Ward W.The pathogenesis of Crohn's isease[J].Lancet,1977,17:903
[15]Shorter RG,Huizenga KA,Spencer RJ.A working hypothesis for the etiology and pathogenesis of nonspecific inflammatory bowel disease[J].Am J Dig Dis,1972,17:1024
[16]巴德年.当代免疫学技术与应用[M].北京:北京医科大学中国协和医科大学联合出版社,1998,894
[17]范少光,等.束缚应激小鼠血中产生的免疫抑制因子及其调节[J].科学通报,1989,(20):1584-1586
[18]李立文,李玉林.溃疡性结肠炎的肠外表现[J].中国煤炭工业医学杂志,2007,10(2):118-119
[19]李怡棠,沈放,白金叶,等.地塞米松、吲哚美辛和白藜芦醇对巴豆油致炎小鼠耳部基质金属蛋白酶-9的抑制作用[J].药学学报,2003,38(7):501-504
[20]滕久祥,彭芝配,尹进,等.九香止泻肠溶片对急性腹泻模型小鼠腹泻指数及腹腔毛细血管通透性影响[J].湖南中医药大学学报,2007,27(6):34-36
[21]王丽娟,李晓蓉,李宇航,等.丹芎方抗炎作用的实验研究[J].医药导报,2008,27(9):1022-1024
[22]祝司霞.复方囊立消胶囊抗炎镇痛作用的实验研究[J].山西中医学院学报,2008,9(5)
[23]朱路,王贵林,姚观平,等.生姜油抗炎和抗超敏反应作用研究[J].时珍国医国药 2007,18(1):1.5-1.6
[24]肖百全,朱少璇,杨威,等.角叉菜胶致大鼠足肿胀模型探讨及其机制研究[J].中国实用医药,2008,3(23):63-65
[25]Hechtman DH,Cybulsky ML,Fuchs HJ,et al.Intravascula IL-8:Inhibitor of polymorphonuclear leukocyte accumulatio at sites of acute inflammation[J].J Immunol.1991, 147(3):883-887.
[26]Indaram AV,Visvalingam V,Loche M,et al.Mucosal cytokine production in radiation-induced proctosigmoiditis compared with inflammatory bowel disease[J].Am J Gastroenterol.2000,95(5):1221.
[27]AkazawaA,SakaidaI,HigakiS,etal.Increased expression of tumor necrosisfactor-alpha messenger RNA in the intestinal mucosa of inflammatory bowel disease,Particularly in patients With disease in the inactive phase[J].JGastroenterol,2002,37(5):345-353.
[28]丁伟群,林庚金,徐三荣,等.溃疡性结肠炎发病中白介素水平的变化[J].复旦学报,2001,28(4):330-333.
[29]崔静,刘占举,唐芙爱.炎症性肠病患者血清肿瘤坏死因子和白介素8检测[J].郑州大学学报(医学版),2006,41(5):826-827.
[30]郭雁冰,王新月,林燕.IL-8与溃疡性结肠炎复发的关系及中药抗复发的研究.新中医,2008,40(2):52-53.
[31]刘晓秋,等.溃疡性结肠炎大鼠大肠一氧化氮产物的检测及意义[J].中国肛肠病学杂志,1999,19(7):6.
[32]章明,等.一氧化氮与溃疡性结肠炎[J].世界华人消化杂志,2000,09,15;8(S:S):104.
[33]孙素群,许霖水.一氧化氮间接作用机制的研究进展[J].生理科学进展,2002,33:167-169.
[34]金惠铭.病理生理学(第5版)[M].北京:人民卫生出版社,2000.150.
[35]李云海,陈园权.结肠康对溃疡性结肠炎大鼠结肠黏膜组织NOS、SOD及MDA的影响[J].中国中医药信息杂志,2001,8(7):37-38.
[36]麦海妍.溃疡性结肠炎血清一氧化氮浓度变化的观察[J].中国肛肠病杂志,2001,21(7):8.
[37]顾立刚.疏肝健脾方对溃疡性结肠炎肝郁脾虚证大鼠结肠溃疡的影响[J].北京中医药大学学报,2000,23(4):24-26.
[38]张永锋,陈如山,吴正治,等.益气活血健脾补肾法对结肠炎小鼠iNOS及其mRNA 表达的影响[J].中医药学刊,2006,24(3):418-419.
[39]吕艺等.肠缺血再灌流大鼠小肠血管内皮细胞ICAM-1表达的变化及其与肠损伤的关系.中华普通外科杂志,2000,15(3):146
[40]Malizia G,Calabrese A,Cottone Met al.Gastroenterology,1991;100(1):150-156
[4]Nielsen OH,Brynskov J,Vainer B,Dig Dis Sci,1996;41(9):1780-1785
[41]VAINER B,NIELSEN O H.Correlation between circulating soluble ICAM-1 and prednisolone-induced amelioration ofulcerativcolitis[J].Stand J Gastroentero,2003,38:283-287.
[42]Bendjelloul F,Rossmann P,etal.Detection of ICAM-1 in experimentally induced colitis of ICAM-1-deficient and wild-type mice:an immunohistochemical study.Histochem J,2000;32(12):703-709
[43]Azueena S,MeritxellG,An tonio S,et al.Nitrio oxide supplementation ameliorates dextran sulfate sodium,induced colitis in mice[J].Lab Invest,2002,82(5):597
[44]Soriano A,Salas A,Salas A,et al.VCAM-1,but not ICAM-1 or MadCAM-1,immunoblockade ameliorates DSS-induced colitis inice[J].Lab Invest,2000,80(10):1541
[45]Taniguchi T,Tsukada H,Nakamura H,et al.Effects of the anti-ICAM-1 monocioned antibody on dextran sodium sulphate induced colitisin rats[J].Gastroenterol Hepatol,1998,13:945
[46]施茵,刘慧荣,龚烨靓,等.针药结合对大鼠溃疡性结肠炎TNF-a、ICAM-1基因表达的影响[J].实用中西医结合临床,2003,3(5):1.
[47]陈友琴,甘华田,欧阳钦,等.抗炎药物对溃疡性结肠炎患者肠黏膜组织NF-KB的活化和细胞粘附分子表达的影响[J].生物医学工程学杂志,2004,21(5):732.
[48]杨栋,刘桂敏.溃疡性结肠炎血栓并发症[J].中华消化杂志,2000,20(2):122.
[49]郑洁.溃疡性结肠炎患者血浆TXB2和6-酮-PGFIa的检测及意叉[J].浙江中医学院学报,2002,26(4):25-26.
[50]中华医学会消化病学分会炎症性肠病协作组.对我国炎症性肠病诊断治疗规范的共识意见[J].胃肠病学,2007,12(8):488-495.
[51]林群莲,黄发盛,李玉闽,等.慢性非特异性结肠炎[J].中国肛肠病杂志,2001,21(7):10-11.
[52]吕永慧,钟东江.溃疡性结肠炎甲皱微循环变化与辨证的内在关系[J].中医药学刊,2003,21(5):658-659.
[53]王浴生,邓文龙,薛春生.中药药理与应用[M].第2版.北京:人民卫生出版社,1998,1010.
[54]王旭丹,袁学勤.肠黏膜免疫调节紊乱介导炎症性肠病的发生[J].世界华人消化杂志,2005,13(18):2257-2262.
[55]Peppelebosch MP,van Deventer SJ T cell apoptosis and inflammatory bowel disease[J].Gut,2004,53(11):1556-1558.
[56]蔡春晓,刘玉兰.溃疡性结肠炎的免疫机制[J].胃肠病学和肝病学杂志,2007,16(5):496-501.
[57]王晓娣.CD_4~+ CD_(25)~+T细胞在溃疡性结肠炎中的表达及其临床意义[J].临床内科杂志,2008,25(1):33-35.
[58]郭敏,王静,王洪武.溃疡性结肠炎大鼠CD_4~+ CD_(25)~+T细胞的改变[J].中华临床医学杂志,2008,9(5):3-6.
[59]安晓霞,崔玉芳,刘萍,等.中药灌肠1号对小鼠结肠炎免疫作用的研究[J].中国中药杂志,2008,33(14):1736-1738
[60]崔玉芳,徐菡,安晓霞,等.T辅助细胞亚群与炎症性肠病的关系[J].世界华人消化杂志,2005,13(20):2464.
[2]罗文纪,陈波.王福仁主任医师治疗溃疡性结肠炎临床经验[J].福建中医药,2006,37(2):22-23.
[3]吴中秋,赵志国,王俊月,等.辨证治疗UC的体会[J].河北中医药学报,2006,21(2):18-19.
[4]戴宝林.UC病因病机探讨及辨证体会[J].天津中医学院学报,2001,20(2):37-38.
[5]焦君良等,从痈论治溃疡性结肠炎初探[J].中国中西医结合脾胃杂志,2000,8(2):100-101
[6]姚小丽,姚雪芬,邹亚君,等辨证论治和施护相结合治疗溃疡性结肠炎[J]浙江中医学院学报,2005,29(2):41-42
[6]曹众毅,邬建平,平衡中焦法治疗溃疡性结肠炎的体会[J].中国医药学报,2003,18(10):617
[7]章浩军,六经辨证治疗溃疡性结肠炎[J].福建中医学院学报,2003(13)2:19
[8]侯高.止泻三合方治疗慢性UC126例[J].新中医,2006,38(1):80.
[9]温如丰.疏肝活血健脾法治疗慢性UC68例[J].陕西中医,2003,24(1):57.
[10]周奚钟.中药治疗慢性UC83例[J].江苏中医,2006,27(4):38.
[11]丁建华.除湿活血汤治疗慢性UC50例[J].中医研究,2006,19(10):37.
[12]杨万里,张晓燕.溃结灵汤治疗慢性UC60例[J].陕西中医,2003,24(7):625.
[13]李小平.中西医结合治疗慢性UC85例总结[J].湖南中医杂志,2006,22(5):20.
[14]傅慧琴,倪士昌.中西医结合治疗UC46例[J].浙江临 床医学,2001,3(8):559.
[15]章红.健脾止泻方保留灌肠治疗慢性UC38例疗效观察[J].河北中医,2006,28(5):336-337.
[16]何长义,王佐军.辨证治疗UC118例[J].河北中医,2005,27(4):267-268.
[17]吕迎春,宋怀春,王玉新,等.中医辨证分型治疗慢性UC37例[J].现代中西医结合杂志,2005,14(8):1047.
[18]张正荣.中西医结合治疗慢性UC36例[J].中国临床医生,2000,28(6):371.
[19]姚小丽,姚雪花,邬亚君,等.辨证论治和施护相结合治疗UC[J].浙江中医学院学报,2005,29(2):41-42.
[20]谭远忠,姜锦林.辨证与辨病治疗UC40例临床观察[J].时珍国医国药,2000,11(3): 261-261.
[21]焦君良,要丽英,孟元勋,等.溃结康胶囊治疗溃疡性结肠炎的临床研究[J].中国中西医结合脾胃杂志,1999,7(3):174
[22]闫惠俊,龙致贤,常章富,韩长柏.中医药治疗溃疡性结肠炎研究进展.中成药[J],2001(23)9:684[
23]于明环.灌肠散保留灌肠治疗UC141例[J].实用中医内科杂志,200418(2):9.
[24]陈庆华.愈溃汤保留灌肠治疗UC[J].山西中医,2004,20(2):43.
[25]黄瑗凤,刘云艳.中药保留灌肠治疗UC68例[J].中国中医药科技,2005,12(1):46.
[26]迟莉丽,隗继武.运用安肠愈疡汤口服合生肌散灌肠治疗UC的临床研究[J].山东中医药大学学报,2004,28(6):787-788.
[27]冯其斌,陈翠萍.中医综合疗法治疗慢性UC59例疗效观察[J].新中医,2003,35(1):26-27.
[28]张府平.中医药治疗UC40例疗效观察[J].湖南中医药导报,2003,9(1):34.
[29]杨顺益.针灸治疗UC的临床观察[J].上海针灸杂志,2001,20(1):17.
[30]杨振辉,张悦,孙英霞.针刺夹脊穴配合梅花针叩刺治疗UC疗效观察[J].中国针灸,2003,23(3):141.
[31]张勤良,刘景峰.针刺夹脊穴配合背俞穴治疗UC95例[J].辽宁中医杂志,2003,30(8):679.
[32]王会珍.针灸综合疗法治疗UC64例[J].上海针灸杂志,2005,24(10):31.
[33]吕明,刘晓艳.推拿三步九法结合针灸治疗慢性UC46例[J].辽宁中医杂志,2005,32(9):951.
[34]王松梅,张立群,孙建.针灸治疗UC的临床效果[J].实用医药杂志,2003,20(2):135.
[35]于荣.温针百会治疗UC[J].浙江中医杂志,1992,(11):522.
[36]李玉琴,高晓明,张智利.穴位埋线治疗慢性结肠炎1190例疗效分析[J].针灸临床杂志,1997,(2):29.
[37]欧阳建东,李明,高静,等.中药栓剂治疗UC的临床研究[J].中国肛肠病杂志,2000,20(7):19.
[38]王璐,李克迪,谭华.中药脐疗辅助治疗UC的临床研究[J].中国肛肠病杂志,2003, 23(7):9.
[39]黄辉.中药灌肠结合肛肠内热磁疗法治疗溃疡性结肠炎40例[J].中国肛肠病杂志,2002,22(7):26.
[1]桑力轩,刘汉立,姜敏.溃疡性结肠炎发病机制研究进展[J].世界华人消化杂志,2007(15):2249-2254.
[2]口锁堂,吴焕淦,施达仁.白介素与溃疡性结肠炎[J].世界华人消化杂志,2006(14):405-411.
[3]崔玉芳,徐菡,安小霞,等.T辅助细胞亚群与炎症性肠病的关系[J].世界华人消化杂 志,2005(13):2464-2468.
[4]庞艳华,郑长青.Th1/Th2细胞亚群与炎症性肠病的关系[J].世界华人消化杂志,2004(12):1922-1924.
[5]张文俊,许国铭,李兆申,等.血清白细胞介素-1B与溃疡性结肠炎的关系[J].第二军医大学学报,2002;23:1345-1347.
[6]Ashwood Harvey R,Veriee T,Wolstencroft R,Thompson RP,Powell JJ.Functional interactions between mucosal IL-1,IL-ra and TGF-beta l in ulcerative colitis[J].Inflamm Res 2004(53):53-59
[7]石敏,吴曙光.白细胞介素1a对多形核白细胞凋亡的抑制作用[J].中国药理学通报,2000(16):455-458
[8]Wu HG,Liu HR,Zhao C Zhan g Wu xF,ZhouS,Shi Y,Liu M.Study on differentially expressed genes of ulcerative colitis in the rat treated by Herbs-partitioned moxibustion[J].Zhong-guo ZheH iu,2005(25):359-365
[9]Sawa Y,Oshitani N,Adachi K,Higuchi k,M at-sumoto T,Arakawa T.Comprehensive analysis of intestinal cytokine m essenger RN A profile by real-tilDe quantitative polvmerase chain reaction in patients with Inflammatory bowel disease[J],Intf MofMed,2003(11):175
[10]钱立平,徐三荣,林庚金,丁伟群.溃疡性结肠炎发病中白介素水平的变化[J].复旦学报(医学科学版)2001(28):330-335
[11]Mittal RD,Bid HK.Ghoshal UC IL-1 receptor antagonist(IL-1Ra)gene polymorphism in patients with inflammatory bowel disease in India[J].Stand 1 Gastroenterol,2005(40):827-831
[12]LudwiczekO,Vannier E,Borggraefe I,KaserA,Siegmund B,Dinarello CA,Tilg H Imbalance betw een interleukin-1 agonists an d an tagonists.,relationship to severity of inflammatory bowel disease[J],ain Exp Immun,2004(138):323-329
[13]W itkin SS,Gerber S,Ledger W,.Influence of interleukin-1 receptor an tagonist gene polymorphism on disease[J].Ctin Infect Dis 2002(34):204-209
[14]Ishizuka Sugimura HommaT,MatsuzawaJ,MochizukiT,KobayashiM,Suzuki K,Otsuka K,Tashiro K,Yamaguchi O,Asakura H.Infl uence of interleukin-10 on the interleukin-1receptor an tagonist/interleukin-1 beta ratio in the colonic mucosa of ulcerative coiltis[J].Diestion 2001(63):22-27
[15]张涛,谢建群.清肠栓对溃疡性结肠炎大鼠血清白介素影响的研究[J].辽宁中医药大 学学报,2006;8(4):50-52.
[16]王晓梅,郊世江,李静,等.溃结宁合剂对溃疡性结肠炎大鼠IL-1β和L1-4的影响[J].山西中医学院学报,2006(7):18-20.
[17]李楠,王雪明,吴凯,等.复方血竭对溃疡性结肠炎模型大鼠细胞因子的调节作用[J].中国中西医结合消化杂志,2007(15):377-379.
[18]朱萱萱,沈洪,施荣山,等.肠安胶囊治疗大鼠免疫性溃疡性结肠炎的实验研究[J].中国中医药科技,2002;9:19-21.
[19]邹阳,王兴友,杨孝芳.溃疡性结肠炎大鼠IL-2、CD44、CD54的实验研究[J].江西医学检验,2002:20:281-282,276.
[20]古学文.溃疡性结肠炎患者血清IL-2及slL-2R浓度变化的研究[J].临床和实验医学杂志,2003,2:153-155.
[21]Van Assche G,Dalle I,Nom an M,et al.A pilot study onthe use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis[J].Am J Gastroenterol 2003:98:375-376.
[22]李桂贤,黄勇华,唐梅文,等.加味柴芍六君颗粒对实验性溃疡性结肠炎大鼠T淋巴细胞亚群及白介素-2的影响[J].广西中医药,2007:30(4):51-53.
[23]段永强,程畅和,成映霞,等.痛泻二草方对溃疡性结肠炎模型大鼠血清IL-2含量及肠黏膜NO含量、NOS活性的影响[J].中国中医药信息杂志,2007;14:34-36.
[24]葛相栓,吴正祥,吴强,等.垂盆草对实验性结肠炎的保护作用及其机制研究[J].中国中西医结合消化杂志2007:15:391-394.
[25]Kitamura 1(,Nakamoto Y,Kan eko S,Mukaida N Pivotal roles of interleukin-6 in transmural inflammation in murine T cell transfer colitis[J].Leukoc Bio,2004:76:1111-1117
[26]邓长生.溃疡性结肠炎患者白细胞介素-6活性研究.中华消化杂志,2001:21:223-225
[27]Raddatz D,Bockemuhl M,Ramadori G.Quantitative measurement of cytokine mRNA in inflammatory bowel disease:relation to clinical and andoscopic activity and outcome[J].Eur,Gastroentero Hepatof 2005:17:547-557
[28]贾百灵,侯晓华.白细胞介素-6与溃疡性结肠炎的关系[J].胃肠病学和肝病学杂志2004;13:217-221.
[29]王伟宁,张熙纯,刘丽.活动期溃疡性结肠炎发病机制的免疫学探讨[J].中国现代医学杂志,2003:13:74-76.
[30]Daig R,Rogler G,Aschenbrenner E,et al.Human intestinal epithelial cells secrete interleukin-1 receptor antagonist and interleukin-8 but not interleukin-1 or imerleukin-6[J].Gut 2000;46:350-358
[31]连建学,刘洁,李洛平,等.结肠安胶囊对实验性溃疡性结肠炎大鼠IL-6、SOD及MDA 表达的影响[J].陕西中医,2006;27:240-241.
[32]祝斌,徐军发,李巧勤,等.阴阳平衡散对溃疡性结肠炎患者血清细胞因子的影响[J].实用全科医学,2007;5:578-579.
[33]吕永慧,胡品津,陈文红,等.中药肠炎清治疗小鼠葡聚糖硫酸钠所致结肠炎的机制[J].世界华人消化杂志,2006;14:1283-1287.
[34]王伟宁,张熙纯,刘丽.活动期溃疡性结肠炎发病机制的免疫学探讨[J].中国现代医学杂志,2003;13:74-78
[35]Imada A,Ina K,Shimada M,Yokoyama T,Yokoyama Y Nishio Y Yamaguchi T Ando T KusugamiK.Coordinate upregulation of interleukin-8 and growth-related gene product-alpha is present in the colonic mucosa of inflammatory bowel[J].Scand 7 Gastroenterol,2001,36:854-864
[36]Tsukada Y,Nakamura T,Iimura M,Iizuka BEHayashi N.Cytokine profile in colonic mucosa of ulcerative co～fis correlates with disease acfivity and response to gran ulocytapheresis[J].Am J Gastroentero,2002;97:2820-2828
[37]屠振兴,李兆申,许国铭,龚燕芳,张文俊.血清白细胞介素-8与溃疡性结肠炎的关系[J].胃肠病学,2002;7:277-279
[38]AkazawaA,Sakaidal,HigakiS,etal.Increased expression of tumor necrosisfactor-alpha messenger RNA in the intestinal mucosa of inflammatory bowel disease,Particularly in patients With disease in the inactive phase[J].JGastroenterol,2002,37(5):345-353.
[39]范恒,邱明义,杨胜兰,梅家俊,沈关心,刘松林.理肠方对溃疡性结肠炎大鼠观察[J].中国中西医结合杂志,2004;12:155
[40]Ishiguro Y.M ucosal proinflam matory cytokine production correlates with endoscopic activity of ulcerafive colitis[J].Gastroenterol,1999,34:66-74
[41]范恒,邱明义,梅家俊,沈关心,刘松林.理肠方对溃疡性结肠炎大鼠组织细胞因子TNF-、IL-6、IL-8 IL-10的影响[J].中医药学刊,2004;22:1624-1628
[42]吴限.结肠灵治疗溃疡性结肠炎的机制研究[J].中国全科医学,2007,10:9699-971.
[43]王新月,杨莉莉,王雪茜,等.溃结饮不同给药途径对溃疡性结肠炎大鼠前炎性细胞因子表达的影响[J].中国中西医结合消化杂志,2006:14:351-354.
[44]郭雁冰,王新月,林燕.I L-8与溃疡性结肠炎复发的关系及中药抗复发的研究[J].新中医,2008,40(2):52-53.
[45]董恩钰,王晓娣.白介素-17在溃疡性结肠炎表达的研究[J].中华消化杂志,2001:21:673-877
[46]Fujino S Andoh A Bamba S Ogawa AHata KAraki Y,Bamba T,Fujiyama Y.Increased expression of interleukin 17 in inflammatory bowel disease[J].Gut 2003:52:65-70
[47]Nielsen OH,Kirman I,Rudiger N,Hendell,VainerB.Upregulation of interleukin-12 and-17in active inflammatory bowel disease[J].Scand,Gastroenterol,2003:38:180-185
[48]Okamura H,Tsutsi H,Komatsu T,Yutsudo M,Hakura A,Tanimoto T,Torigoe K,Okura T,Nukada Y.Ha～ofi K.Cloning of a new cytokine th at induces IFN-gam ma production byT cells[J].Nature,1995:378:88-91
[49]张丁丁,游自立,杨明清,等.溃疡性结肠炎患者血清IL-18的变化及意义[J].现代中西医结合杂志,2002;11:586-588.
[50]郭晓东,关庆.增加味四逆散对溃疡性结肠炎肝郁大鼠模型血清IL-4、IL-10的影响研究[J].中医药学刊,2004,22:659-662
[51]丁晓刚.黄芩汤有效成分配方对大鼠实验性溃疡性结肠炎的免疫调节作用[J].中医药学刊,2003:21:126.127
[52]Ten Hove T The Olie F Berkhout M Bruggeman JP,Vyth-Dreese FA,Slors JF,Van Deventer SJ,TVelde AA.Expression of CI)45RB functionally distinguishes intestinal T lymphocytes in -ulflarnmatory bowel disease[J].Leukoc Biof,2004,75:1010-1015
[53]Rermick DM,Fort MM.Lessons from genetically engineered anim al m odels.Ⅻ.1L-10-deficient(IL-10mice and intestinal inflammation[J].Am,Physiol Gastrointest Liver Physiol 2000,278:G829.G833
[54]Bene L Sapi Z Bajtai A.Buzas.Szentmihalyi.Arato A,Tulassay Z,Falus A.Partial protection against dextran sodium sulphate induced colitis in histam ine—deficient,histidine decarboxylase knockout mice[J].Pediatr Gastroenterol Nutr,2004,39:171-176
[55]霍丽娼,赵和平.实验性溃疡性结肠炎大鼠模型的研究[J].山西医科大学学报,2004,35:467-470
[56]Li M C,He SH.IL-10 and its related cytokines for treatment of inflammatory bowel disease[J].World,Gastroenterol,2004,10:620-625
[57]董文毅,胡刚正,郑长青.补脾清肠活血汤对溃疡性结肠炎患者淋巴细胞功能的影响[J].世界华人消化杂志,2006,14:1124-1127.
[58]Fuss II,Heller F,Boirivant M,Leon F,Yoshida M,Fichtner-Feigl s Yang Z.Exley M Kitani.Blum-berg RS,Marmon P,Strober W.Nonclassical CDldrestricted NK T cells that produce IL.13 characterize an atypical Th2 response in ulcerative colitis[J].Jclin Invest 2004,113:1490-1497
[59]Heller F,Florian P,B0iars C Richter J,Christ M,Hillenbran d B,Mankertz J,Gitter Burgel N,Fromm M,Zeitz M,Fuss I,Strober W,Schulzke ID.Interleu-kin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial fightjunctions,apoptosis,and cell restitution[J].GastroenteroloyoI 2005,129:550-564
[60]Targan SR.Karp LC.Defects in mucosal imm unity leading to ulcerative colitis[J].ImmunolRev,2005,206:296-305
[61]Lugering N,Kucharzik T,Kraft M,Winde G,Sorg C Stoll R,Domschke W.Interleukin IL-13 and IL-4 are potent inhibitors of IL-8 secretion by human intestinal epithelial cells[J].Dig Dis Sci,1999,44:649-655
[62]Vainer B,Nielsen oH,Hendel I,Horn T,Kirman I.Colonic expression an d synthesis of interleukin 13 and interleukin 15 in inflam matory bowel disease[J].Cvtokine,2000,12:1531-1536
[63]周字,叶文桃,麦海妍,郭汉城,王翠霞.白介素13和一氧化氮在溃疡性结肠炎的作用及意义[J].胃肠病学和肝病学杂志,2004,13:319-322
[1]闷萍,乐进秋,江汉.细胞粘附分子ICAM-Ⅰ在慢性牙周炎牙龈组织中自细胞的表达[J].广东牙病防治,2003;11(1):18-19.
[2]MaliziaG,CalabreseA,CottoneM,etal.Gastroenterology,1991,100(1):150-156
[3]费保莹,邓长生,朱尤庆.细胞粘附分子与炎症性肠病[J].国外医学:消化系疾病分册,1999;19(1):15-17.
[4]NieisenOH,BrynskovJ.VainerBDigDisSei,1996,41(9):1780-1785
[5]陈志贵,等.炎性肠病研究的展望[J].美国医学会杂志:中文版,2002;21(2):72.
[6]MaliziaG,CalabreseA,CottoneM,etal.Expressionofleukocyteadhesionmoleculesbymucosalmo nonuclearphagocytesininflammatoryboweldisease[J].Gastroenterology,1991,100:150
[7]施茵,刘慧荣,龚烨靓等.针药结合对大鼠溃疡性结肠炎TNF-a、ICAM-1基因表达的影响[J].实用中西医结合临床,2003;3(5):1-3.
[8]牛凤丽,郑萍,刘文忠,施尧.葡聚糖硫酸钠诱导大鼠结肠炎发病机制的研究[J].胃肠病学,2003:008(005).283-286.
[9]BendjelloulF.Rossmann P,MalyP.MandysV,JirkovskaM,Prokesova L.Tlaskalova Hogenova H.Detection ofICAM-ldeficient and wildtype m ice:an im munohistochemical study[J].Histochem J.2000,32:703-709.
[10]BendijelloulF,MalyP.MandysV,JirkovskaM,ProkesovaL,Tuckova L,TlaskalovaHogenovaHIntercellular dhesionmolecule-1(ICAM-1) deficiency protects mice against severe forms of xperimentally induced colitis[J].Clin Exp Im munol,2000;119:57-63.
[11]Mori N,Horie Y,Gerritsen ME,et al.Anti-inflammatory drugs and endothelial cell adhesion molecule expression in murine vascular beds[J].Gut,1999,44(2):186-195
[12]江学良,权启镇,孙自勤,等.糖皮质激素对重度溃疡性结肠炎患者淋巴细胞粘附分子表达的影响[J].中国危重病急救医学,1998,10(6):366
[13]Wittig B,Seiter S,Schmidt DS,et al.CD44 variant isoforms on blood leukocytes in chronic inflammatory bowel disease and other systemic autoimmune diseases[J].Lab Invest,1999,79(6):747-759
[14]CartyE,Macey M,Rampton DS.Inhibition of platelet activation by 5-aminosalicylic acid in inflammatory bowel disease[J].Aliment Pharmacol Ther,2000,14(9):1169-1179
[15]Fagerstam JP,Whiss PA,Strom M,et al.Expression of platelet P-selectin and ditection of soluble P-selectin,NPY and RANTES in patients with inflammatory bowel disease[J].Inflamm Res,2000,49(9):466-472
[16]Soriano A,Salas A,SalasA,etal.VCAM-1,but not ICAM-1 or MadCAM-1,immunoblockade ameliorates DSS-induced colitis in mice[J].Lab Invest,2000,80(10):1541-1551
[17]Taniguchi T.T sukada H.Kodam a M,Fukuda K,Saito T,M iyasaka M.Seino Y.Effects ofthe anti-ICAM-1 monocIonalantibody on dextrsm sodium sulphate-induced colitisin rats[J].JGastroenterolHepatol,1998;13:945-949.
[18]Wong PY etal.J Pharmacol Exp Ther,1995;274(1):475-480.
[19]杜群,李红,王汝俊等,溃结灵对溃疡性结肠炎大鼠结肠黏膜ICAM-1基因表达的作用[J].广州中医药大学学报,2008:25(3):229-232
[20]施茵,刘慧荣,龚烨靓,等.针药结合对大鼠溃疡性结肠炎TNF-a、ICAM-1基因表达的影响[J].实用中西医结合临床,2003,3(5):1.
[21]陈友琴,甘华田,欧阳钦,等.抗炎药物对溃疡性结肠炎患者肠黏膜组织NF-KB的活化和细胞粘附分子表达的影响[J].生物医学工程学杂志,2004,21(5):732.
[22]郑红斌,胡鸿毅,马贵同,清肠栓对溃疡性结肠炎实验大鼠ICAM-1表达的影响[J]. 浙江中医学院学报,2004,28(6):44-46
[23]赵晓霞,郭胜,李宝鹤等,芍药汤对溃疡性结肠炎大鼠ICAM-1、TNF-a、IL-10影响的实验研究[J].中国中医药科技,2008,15(3):174-175
[1]中华医学会消化病学分会炎症性肠病协作组.对我国炎症性肠病诊断治疗规范的共识意见[J].胃肠病学,2007,12(8):488-495.
[2]李桂珍,江必武,胡伟,等.猴头菌提取物颗粒治疗轻中度溃疡性结肠炎80例疗效观察[J].临床消化病杂志,2007,19(2):113-114.
[3]于成功,徐肇敏,祝其凯,等.猴头菌对实验大鼠胃粘膜保护作用的研究[J].胃肠病学,1999,4(2):93-96.
[4]王贤蕙,范秀容.猴头菌多糖对T淋巴细胞的调节作用.中国实验临床免疫学杂志,1990,2(4):40-43.
[5]许立,倪正,方泰惠,等.苍术胶囊抗炎免疫作用研究[J].陕西中医,2005,26(7):719-721.
[6]李曼玲,范莉,冯伟红,等.苍术的化学药理研究进展[J].中国中医药信息杂志,2002,11(9):79-82.
[7]朱自平,张明发,沈雅琴,等.厚朴对消化系统的药理作用[J].中国中药杂志,1997,22(11):686-688.
[8]谭永红,王诗华,梁容梅.中药半枝莲的研究进展[J].西南国防医药,2002,12(2):152-153.
[9]龚黎,于成功,杨珺.中药预处理对结肠炎模型大鼠的免疫调节效应[J].胃肠病学,2008,13(6):364-367.
[10]Morris GP,Beck PL,Herridge MS,et al.Hapten induced model of chronic inflannation and ulceration in the rat colon[J].Gastroenterology,1989,96:795
[11]Little JR,Eisen HN.Preparation and characterization of antibodies specific for the 2,4,6-trinitrophenyl group[J].Biochemistry,1996;5:3385-3395
[12]Fidler JM.Induction of hapten-specific immunological toleranct and immunity in Blymphocyes Ⅶ.correlation between trinitrobenzenesulfonic acid administration,serum trinitrophenyl content and level of tolerance[J].Cell Immunal,1985;94:285-291
[13]朱峰,钱家鸣,潘国宗.细胞免疫反应性炎症性肠病动物模型的建立[J].中国医学科学院学报,1998,20(4):271-278
[14]郑礼,高振强,王淑仙.大鼠溃疡性结肠炎模型的实验研究[J].中国药理学通,199,14(4):3706.Ward W.The pathogenesis of Crohn's isease[J].Lancet,1977,17:903
[15]Shorter RG,Huizenga KA,Spencer RJ.A working hypothesis for the etiology and pathogenesis of nonspecific inflammatory bowel disease[J].Am J Dig Dis,1972,17:1024
[16]巴德年.当代免疫学技术与应用[M].北京:北京医科大学中国协和医科大学联合出版社,1998,894
[17]范少光,等.束缚应激小鼠血中产生的免疫抑制因子及其调节[J].科学通报,1989,(20):1584-1586
[18]李立文,李玉林.溃疡性结肠炎的肠外表现[J].中国煤炭工业医学杂志,2007,10(2):118-119
[19]李怡棠,沈放,白金叶,等.地塞米松、吲哚美辛和白藜芦醇对巴豆油致炎小鼠耳部基质金属蛋白酶-9的抑制作用[J].药学学报,2003,38(7):501-504
[20]滕久祥,彭芝配,尹进,等.九香止泻肠溶片对急性腹泻模型小鼠腹泻指数及腹腔毛细血管通透性影响[J].湖南中医药大学学报,2007,27(6):34-36
[21]王丽娟,李晓蓉,李宇航,等.丹芎方抗炎作用的实验研究[J].医药导报,2008,27(9):1022-1024
[22]祝司霞.复方囊立消胶囊抗炎镇痛作用的实验研究[J].山西中医学院学报,2008,9(5)
[23]朱路,王贵林,姚观平,等.生姜油抗炎和抗超敏反应作用研究[J].时珍国医国药 2007,18(1):1.5-1.6
[24]肖百全,朱少璇,杨威,等.角叉菜胶致大鼠足肿胀模型探讨及其机制研究[J].中国实用医药,2008,3(23):63-65
[25]Hechtman DH,Cybulsky ML,Fuchs HJ,et al.Intravascula IL-8:Inhibitor of polymorphonuclear leukocyte accumulatio at sites of acute inflammation[J].J Immunol.1991, 147(3):883-887.
[26]Indaram AV,Visvalingam V,Loche M,et al.Mucosal cytokine production in radiation-induced proctosigmoiditis compared with inflammatory bowel disease[J].Am J Gastroenterol.2000,95(5):1221.
[27]AkazawaA,SakaidaI,HigakiS,etal.Increased expression of tumor necrosisfactor-alpha messenger RNA in the intestinal mucosa of inflammatory bowel disease,Particularly in patients With disease in the inactive phase[J].JGastroenterol,2002,37(5):345-353.
[28]丁伟群,林庚金,徐三荣,等.溃疡性结肠炎发病中白介素水平的变化[J].复旦学报,2001,28(4):330-333.
[29]崔静,刘占举,唐芙爱.炎症性肠病患者血清肿瘤坏死因子和白介素8检测[J].郑州大学学报(医学版),2006,41(5):826-827.
[30]郭雁冰,王新月,林燕.IL-8与溃疡性结肠炎复发的关系及中药抗复发的研究.新中医,2008,40(2):52-53.
[31]刘晓秋,等.溃疡性结肠炎大鼠大肠一氧化氮产物的检测及意义[J].中国肛肠病学杂志,1999,19(7):6.
[32]章明,等.一氧化氮与溃疡性结肠炎[J].世界华人消化杂志,2000,09,15;8(S:S):104.
[33]孙素群,许霖水.一氧化氮间接作用机制的研究进展[J].生理科学进展,2002,33:167-169.
[34]金惠铭.病理生理学(第5版)[M].北京:人民卫生出版社,2000.150.
[35]李云海,陈园权.结肠康对溃疡性结肠炎大鼠结肠黏膜组织NOS、SOD及MDA的影响[J].中国中医药信息杂志,2001,8(7):37-38.
[36]麦海妍.溃疡性结肠炎血清一氧化氮浓度变化的观察[J].中国肛肠病杂志,2001,21(7):8.
[37]顾立刚.疏肝健脾方对溃疡性结肠炎肝郁脾虚证大鼠结肠溃疡的影响[J].北京中医药大学学报,2000,23(4):24-26.
[38]张永锋,陈如山,吴正治,等.益气活血健脾补肾法对结肠炎小鼠iNOS及其mRNA 表达的影响[J].中医药学刊,2006,24(3):418-419.
[39]吕艺等.肠缺血再灌流大鼠小肠血管内皮细胞ICAM-1表达的变化及其与肠损伤的关系.中华普通外科杂志,2000,15(3):146
[40]Malizia G,Calabrese A,Cottone Met al.Gastroenterology,1991;100(1):150-156
[4]Nielsen OH,Brynskov J,Vainer B,Dig Dis Sci,1996;41(9):1780-1785
[41]VAINER B,NIELSEN O H.Correlation between circulating soluble ICAM-1 and prednisolone-induced amelioration ofulcerativcolitis[J].Stand J Gastroentero,2003,38:283-287.
[42]Bendjelloul F,Rossmann P,etal.Detection of ICAM-1 in experimentally induced colitis of ICAM-1-deficient and wild-type mice:an immunohistochemical study.Histochem J,2000;32(12):703-709
[43]Azueena S,MeritxellG,An tonio S,et al.Nitrio oxide supplementation ameliorates dextran sulfate sodium,induced colitis in mice[J].Lab Invest,2002,82(5):597
[44]Soriano A,Salas A,Salas A,et al.VCAM-1,but not ICAM-1 or MadCAM-1,immunoblockade ameliorates DSS-induced colitis inice[J].Lab Invest,2000,80(10):1541
[45]Taniguchi T,Tsukada H,Nakamura H,et al.Effects of the anti-ICAM-1 monocioned antibody on dextran sodium sulphate induced colitisin rats[J].Gastroenterol Hepatol,1998,13:945
[46]施茵,刘慧荣,龚烨靓,等.针药结合对大鼠溃疡性结肠炎TNF-a、ICAM-1基因表达的影响[J].实用中西医结合临床,2003,3(5):1.
[47]陈友琴,甘华田,欧阳钦,等.抗炎药物对溃疡性结肠炎患者肠黏膜组织NF-KB的活化和细胞粘附分子表达的影响[J].生物医学工程学杂志,2004,21(5):732.
[48]杨栋,刘桂敏.溃疡性结肠炎血栓并发症[J].中华消化杂志,2000,20(2):122.
[49]郑洁.溃疡性结肠炎患者血浆TXB2和6-酮-PGFIa的检测及意叉[J].浙江中医学院学报,2002,26(4):25-26.
[50]中华医学会消化病学分会炎症性肠病协作组.对我国炎症性肠病诊断治疗规范的共识意见[J].胃肠病学,2007,12(8):488-495.
[51]林群莲,黄发盛,李玉闽,等.慢性非特异性结肠炎[J].中国肛肠病杂志,2001,21(7):10-11.
[52]吕永慧,钟东江.溃疡性结肠炎甲皱微循环变化与辨证的内在关系[J].中医药学刊,2003,21(5):658-659.
[53]王浴生,邓文龙,薛春生.中药药理与应用[M].第2版.北京:人民卫生出版社,1998,1010.
[54]王旭丹,袁学勤.肠黏膜免疫调节紊乱介导炎症性肠病的发生[J].世界华人消化杂志,2005,13(18):2257-2262.
[55]Peppelebosch MP,van Deventer SJ T cell apoptosis and inflammatory bowel disease[J].Gut,2004,53(11):1556-1558.
[56]蔡春晓,刘玉兰.溃疡性结肠炎的免疫机制[J].胃肠病学和肝病学杂志,2007,16(5):496-501.
[57]王晓娣.CD_4~+ CD_(25)~+T细胞在溃疡性结肠炎中的表达及其临床意义[J].临床内科杂志,2008,25(1):33-35.
[58]郭敏,王静,王洪武.溃疡性结肠炎大鼠CD_4~+ CD_(25)~+T细胞的改变[J].中华临床医学杂志,2008,9(5):3-6.
[59]安晓霞,崔玉芳,刘萍,等.中药灌肠1号对小鼠结肠炎免疫作用的研究[J].中国中药杂志,2008,33(14):1736-1738
[60]崔玉芳,徐菡,安晓霞,等.T辅助细胞亚群与炎症性肠病的关系[J].世界华人消化杂志,2005,13(20):2464.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |